Document is current
Any future updates will be listed below
-
Authors
Morath, Volker https://orcid.org/0000-0001-7636-0537
Fritschle, Katja
Warmuth, Linda
Anneser, Markus
Dötsch, Sarah
Živanić, Milica https://orcid.org/0000-0002-4967-5709
Krumwiede, Luisa https://orcid.org/0000-0001-5695-1575
Bösl, Philipp
Bozoglu, Tarik https://orcid.org/0000-0002-6545-2150
Robu, Stephanie
Libertini, Silvana https://orcid.org/0000-0003-2633-1564
Kossatz, Susanne
Kupatt, Christian https://orcid.org/0000-0002-3611-1218
Schwaiger, Markus
Steiger, Katja https://orcid.org/0000-0002-7269-5433
Busch, Dirk H. https://orcid.org/0000-0001-8713-093X
Skerra, Arne https://orcid.org/0000-0002-5717-498X
Weber, Wolfgang A. https://orcid.org/0000-0002-7854-4345
-
Funding
Funding for this research was provided by:
National Centre for the Replacement Refinement and Reduction of Animals in Research (NC/C01905/1, NC/C019202/1, NC/C01905/1, NC/C019202/1, NC/C01905/1, NC/C019202/1, NC/C01905/1, NC/C019202/1, NC/C01905/1, NC/C019202/1)
- License Information
-
More Information
Article History
Received: 31 July 2023
Accepted: 2 April 2025
First Online: 13 June 2025
Competing interests
: V.M., K.F., A.S. and W.A.W. have applied for intellectual property rights on Anticalin-based reporter genes (WO 20022/101492 A1). A.S. is a co-founder and shareholder of Pieris Pharmaceuticals. The other authors declare no competing interests.
